<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751487</url>
  </required_header>
  <id_info>
    <org_study_id>EFC16819</org_study_id>
    <secondary_id>2020-001819-24</secondary_id>
    <secondary_id>U1111-1250-2843</secondary_id>
    <nct_id>NCT04751487</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      Primary population (former smokers cohort):&#xD;
&#xD;
        -  Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of&#xD;
           acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe&#xD;
           COPD&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      Primary population (former smokers cohort):&#xD;
&#xD;
        -  Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in&#xD;
           former smokers with moderate-to-severe COPD&#xD;
&#xD;
        -  Evaluate the efficacy of itepekimab compared with placebo on occurrence of acute&#xD;
           exacerbation of COPD (AECOPD) in former smokers with moderate-to-severe COPD&#xD;
&#xD;
        -  Evaluate the efficacy of itepekimab compared with placebo on severe AECOPD in former&#xD;
           smokers with moderate-to-severe COPD&#xD;
&#xD;
        -  Evaluate the efficacy of itepekimab compared with placebo on corticosteroid-treated&#xD;
           AECOPD in former smokers with moderate-to-severe COPD&#xD;
&#xD;
        -  Evaluate the efficacy of itepekimab compared with placebo on respiratory symptoms in&#xD;
           former smokers with moderate-to-severe COPD&#xD;
&#xD;
        -  Evaluate the efficacy of itepekimab compared with placebo on Forced Expiratory Volume in&#xD;
           1 second (FEV1) slope in former smokers with moderate-to-severe COPD&#xD;
&#xD;
        -  Evaluate the efficacy of itepekimab compared with placebo on health-related quality of&#xD;
           life (HRQoL) as assessed by St. George's Respiratory Questionnaire (SGRQ) in former&#xD;
           smokers with moderate-to-severe COPD&#xD;
&#xD;
        -  Evaluate the safety and tolerability of itepekimab in former smokers with&#xD;
           moderate-to-severe COPD&#xD;
&#xD;
        -  Evaluate the pharmacokinetic (PK) profile of itepekimab in former smokers with&#xD;
           moderate-to-severe COPD&#xD;
&#xD;
        -  Evaluate immunogenicity to itepekimab in former smokers with moderate-to-severe COPD&#xD;
&#xD;
      Secondary population (current smokers cohort)&#xD;
&#xD;
        -  Estimate the efficacy of itepekimab compared with placebo on the annualized rate of&#xD;
           acute moderate or severe COPD exacerbations in current smokers with moderate-to-severe&#xD;
           COPD&#xD;
&#xD;
        -  Estimate the efficacy of itepekimab compared with placebo on pulmonary function in&#xD;
           current smokers with moderate-to-severe COPD&#xD;
&#xD;
        -  Estimate the safety and tolerability of itepekimab in current smokers with&#xD;
           moderate-to-severe COPD&#xD;
&#xD;
        -  Estimate the PK profile of itepekimab in current smokers with moderate to severe COPD&#xD;
&#xD;
        -  Estimate immunogenicity to itepekimab in current smokers with moderate-to-severe COPD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration per participant is approximatively 76 weeks including a 3-to-5-week&#xD;
      screening period, a 52-week treatment period on investigational medicinal product (IMP) and a&#xD;
      20-week post-IMP treatment follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD) in former smokers</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD) over the 52-week placebo-controlled treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at Week 52 in former smokers</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in post-BD FEV1 at Week 52 in former smokers</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-BD FEV1 at Week 24 in former smokers</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first moderate or severe AECOPD in former smokers</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Time to first moderate or severe AECOPD over the 52 week placebo-controlled treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of severe AECOPD in former smokers</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Annualized rate of severe AECOPD over the 52 week placebo-controlled treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first severe AECOPD in former smokers</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Time to first severe AECOPD over the 52-week placebo-controlled treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of corticosteroid-treated AECOPD in former smokers</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Annualized rate of corticosteroid-treated AECOPD over the 52-week placebo-controlled treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) total score at Week 52 in former smokers</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The E-RS: COPD is administered as a part of the 14-item EXACT questionnaire and is completed on a daily basis.The 11-item E-RS:COPD assesses severity of respiratory symptoms overall and severity of individual symptoms such as breathlessness, cough and sputum, and chest symptoms The total score of E-RS:COPD ranges from 0 to 40, with higher values indicating more severe respiratory symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in post-BD FEV1 (L) from baseline (post-BD FEV1 slope) in former smokers</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score at Week 52 in former smokers</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The SGRQ is a 50-item questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation. A global score ranges from 0 to 100. Scores by dimension are calculated for 3 domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. A lower score indicates better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a decrease from baseline of at least 4 points in SGRQ total score at Week 52 in former smokers</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The SGRQ is a 50-item questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation. A global score ranges from 0 to 100. Scores by dimension are calculated for 3 domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. A lower score indicates better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs), adverse event of special interests (AESIs), serious adverse events (SAEs), and adverse events (AEs) leading to permanent treatment discontinuation in former smokers</measure>
    <time_frame>Baseline up to end of study (Week 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of potentially clinically significant laboratory test, vital signs, and electrocardiogram (ECGs) abnormalities in former smokers</measure>
    <time_frame>Baseline up to end of study (Week 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional itepekimab concentrations in serum in former smokers</measure>
    <time_frame>Baseline up to end of study (Week 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent anti-itepekimab antibodies responses in former smokers</measure>
    <time_frame>Baseline up to end of study (Week 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of moderate or severe AECOPD in current smokers</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Annualized rate of moderate or severe AECOPD over the 52 week placebo-controlled treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-BD FEV1 at Week 52 in current smokers</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation in current smokers</measure>
    <time_frame>Baseline up to end of study (Week 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of potentially clinically significant laboratory, vital signs, and ECGs abnormalities in current smokers</measure>
    <time_frame>Baseline up to end of study (Week 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional itepekimab concentrations in serum in current smokers</measure>
    <time_frame>Baseline up to end of study (Week 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent anti-itepekimab antibodies responses in current smokers</measure>
    <time_frame>Baseline up to end of study (Week 72)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1170</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Itepekimab Q2W in former smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Itepekimab Q4W in former smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC administration of Itepekimab every 4 weeks (Q4W) for 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in former smokers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC administration of matching placebo Q2W for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Itepekimab Q2W in current smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC administration of Itepekimab every 2 weeks (Q2W) for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in current smokers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC administration of matching placebo Q2W for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itepekimab SAR440340</intervention_name>
    <description>Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous</description>
    <arm_group_label>Itepekimab Q2W in current smokers</arm_group_label>
    <arm_group_label>Itepekimab Q2W in former smokers</arm_group_label>
    <arm_group_label>Itepekimab Q4W in former smokers</arm_group_label>
    <other_name>REGN3500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous</description>
    <arm_group_label>Placebo in current smokers</arm_group_label>
    <arm_group_label>Placebo in former smokers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Participant must be 40 to 85 years of age inclusive.&#xD;
&#xD;
          -  Physician diagnosis of COPD for at least 1 year (based on Global Initiative for&#xD;
             Chronic Obstructive Lung Disease [GOLD] definition.&#xD;
&#xD;
          -  Smoking history of ≥10 pack-years:&#xD;
&#xD;
               -  For former smokers: participants who report that they are not currently smoking&#xD;
                  and smoking cessation must have occurred ≥6 months prior to Screening (Visit 1A)&#xD;
                  with an intention to quit permanently.&#xD;
&#xD;
               -  For current smokers: participants who report that they are currently smoking&#xD;
                  tobacco (participant smoked at least 1 cigarette per day on average during the&#xD;
                  past 7 days) at Screening (Visit 1A) and who are not currently participating in&#xD;
                  or planning to initiate a smoking cessation intervention at Screening (Visit 1A)&#xD;
                  or during Screening period.&#xD;
&#xD;
          -  Participants with moderate-to-severe COPD&#xD;
&#xD;
          -  Participant-reported history of signs and symptoms of chronic bronchitis (chronic&#xD;
             productive cough for at least 3 months in the year prior to Screening in a participant&#xD;
             in whom other causes of chronic cough [eg, inadequately treated gastroesophageal&#xD;
             reflux or chronic rhinosinusitis; or clinical diagnosis of bronchiectasis] has been&#xD;
             excluded).&#xD;
&#xD;
          -  Documented history of high exacerbation risk defined as having had ≥2 moderate or ≥1&#xD;
             severe exacerbations within the year prior to Screening (Visit 1A), with at least 1&#xD;
             exacerbation treated with systemic corticosteroids. At least one exacerbation must&#xD;
             have occurred while participants were on their current controller therapy:&#xD;
&#xD;
               -  Moderate exacerbations will be recorded by the Investigator and are defined as&#xD;
                  acute worsening of respiratory symptoms that requires either systemic&#xD;
                  corticosteroids (IM, IV, or oral) and/or antibiotics.&#xD;
&#xD;
               -  Severe exacerbations will be recorded by the Investigator and are defined as&#xD;
                  AECOPD that require hospitalization or observation for &gt;24 hours in emergency&#xD;
                  department/urgent care facility.&#xD;
&#xD;
          -  Participants with standard of care controller therapy, for ≥3 months prior to&#xD;
             Screening (Visit 1A) and at a stable dose of controller therapy for at least 1 month&#xD;
             prior to the Screening, including either: inhaled corticosteroid (ICS) + long-acting&#xD;
             beta-agonist (LABA), long-acting muscarinic antagonist (LAMA) + LABA or LAMA + LABA +&#xD;
             ICS. -- Body mass index (BMI) ≥18.0 kg/m^2&#xD;
&#xD;
          -  Female participant is not pregnant, not breastfeeding, and at least one of the&#xD;
             following conditions applies:&#xD;
&#xD;
               -  not a women of child-bearing potential (WOCBP) OR&#xD;
&#xD;
               -  a WOCBP who agrees to follow the contraceptive guidance during the intervention&#xD;
                  period and for at least 20 weeks after the last dose of study intervention. -&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Current diagnosis of asthma according to the Global Initiative for Asthma (GINA)&#xD;
             guidelines, or documented history of asthma.&#xD;
&#xD;
          -  For former smokers: Active smoking or vaping of any products (eg, nicotine,&#xD;
             tetrahydrocannabinol [THC]) within 6 months prior to Screening (Visit 1A).&#xD;
&#xD;
          -  For current smokers: vaping of any products (eg, nicotine, THC) within 6 months prior&#xD;
             to Screening (Visit 1A).&#xD;
&#xD;
          -  Clinically significant new abnormal electrocardiogram (ECG) within 6 months prior to,&#xD;
             or at Screening (Visit 1A) that may affect the participant's participation in the&#xD;
             study.&#xD;
&#xD;
          -  Clinically significant and current pulmonary disease other than COPD, eg, sarcoidosis,&#xD;
             interstitial lung disease, bronchiectasis (clinical diagnosis), diagnosis of α-1&#xD;
             anti-trypsin deficiency, or another diagnosed pulmonary disease.&#xD;
&#xD;
          -  Diagnosis of cor pulmonale, evidence of right cardiac failure, or moderate-to-severe&#xD;
             pulmonary hypertension.&#xD;
&#xD;
          -  Hypercapnia requiring bilevel positive airway pressure (BiPAP).&#xD;
&#xD;
          -  Moderate or severe exacerbation of COPD (AECOPD) within 4 weeks prior to Screening&#xD;
             (Visit 1A).&#xD;
&#xD;
          -  Prior history of / planned: lung pneumonectomy for any reason, or lung volume&#xD;
             reduction procedures (including bronchoscopic volume reduction) for COPD. Note:&#xD;
             Surgical biopsy, or segmentectomy, or wedge resection, or lobectomy for other diseases&#xD;
             would not be excluded.&#xD;
&#xD;
          -  Unstable ischemic heart disease, including acute myocardial infarction within the past&#xD;
             1 year prior to Screening, or unstable angina in the 6 months prior to Screening&#xD;
             (Visit 1A).&#xD;
&#xD;
          -  Cardiac arrhythmias including paroxysmal (eg, intermittent) atrial fibrillation.&#xD;
&#xD;
          -  Uncontrolled hypertension (ie, systolic blood pressure [BP] &gt;180 mm Hg or diastolic BP&#xD;
             &gt;110 mm Hg with or without use of anti-hypertensive therapy).&#xD;
&#xD;
          -  Participants with active tuberculosis (TB), latent TB, a history of incompletely&#xD;
             treated TB, suspected extrapulmonary TB infection (TBI), or who are at high risk of&#xD;
             contracting TB (such as close contact with individuals with active or latent TB) or&#xD;
             received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening&#xD;
             (Visit 1A).&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology&#xD;
             at Screening (Visit 1A).&#xD;
&#xD;
          -  Suspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection or in&#xD;
             contact with known exposure to COVID-19 at Screening (Visit 1A); known history of&#xD;
             COVID-19 infection within 4 weeks prior to Screening (Visit 1A); history of requiring&#xD;
             mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to&#xD;
             COVID-19 within 3 months prior to Screening (Visit 1A); participants who have had a&#xD;
             COVID-19 infection prior Screening (Visit 1A) who have not yet sufficiently recovered&#xD;
             to participate in the procedures of a clinical trial.&#xD;
&#xD;
          -  Evidence of acute or chronic infection requiring systemic treatment with anti&#xD;
             bacterial, antiviral, antifungal, antiparasitic, or antiprotozoal medications within 4&#xD;
             weeks before Screening (Visit 1A), significant viral infections within 4 weeks before&#xD;
             Screening (Visit 1A) that may not have been treated with antiviral treatment (eg,&#xD;
             influenza receiving only symptomatic treatment).&#xD;
&#xD;
          -  Participants with active autoimmune disease or participants using immunosuppressive&#xD;
             therapy for autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease,&#xD;
             primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis.&#xD;
&#xD;
          -  History of malignancy within 5 years before Screening (Visit 1A), except completely&#xD;
             treated in situ carcinoma of the cervix, completely treated and resolved nonmetastatic&#xD;
             squamous or basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Previous use of itepekimab.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400011</name>
      <address>
        <city>Greenacres City</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400007</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400005</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400004</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1000005</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240020</name>
      <address>
        <city>Burlington</city>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240003</name>
      <address>
        <city>Quebec</city>
        <zip>G1N 4V3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240005</name>
      <address>
        <city>St-Charles Borrommee</city>
        <zip>J6E 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240009</name>
      <address>
        <city>Toronto</city>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Trois-Rivieres</city>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240002</name>
      <address>
        <city>Victoriaville</city>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240018</name>
      <address>
        <city>Windsor</city>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760004</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760006</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760003</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920016</name>
      <address>
        <city>Shinagawa-Ku</city>
        <zip>140-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430001</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430006</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

